pyrazines has been researched along with azd7687 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Denison, H; Eriksson, JW; Karlsson, C; Knutsson, M; Kujacic, M; Löfgren, L; Nilsson, C | 1 |
| Barlind, JG; Bauer, UA; Birch, AM; Birtles, S; Buckett, LK; Butlin, RJ; Davies, RD; Eriksson, JW; Hammond, CD; Hovland, R; Johannesson, P; Johansson, MJ; Kemmitt, PD; Lindmark, BT; Morentin Gutierrez, P; Noeske, TA; Nordin, A; O'Donnell, CJ; Petersson, AU; Redzic, A; Turnbull, AV; Vinblad, J | 1 |
| Al-Shurbaji, A; Denison, H; Eriksson, JW; Himmelmann, A; Knutsson, M; Löfgren, L; Mårtensson, G; Nilsson, C; Tornqvist, H | 1 |
| Floettmann, E; Jones, HB; Lees, D; Seeliger, F | 1 |
| Jauhiainen, A; Taib, Z | 1 |
| Birtles, S; Morentin Gutierrez, P; Nilsson, C; Yates, J | 1 |
2 trial(s) available for pyrazines and azd7687
| Article | Year |
|---|---|
Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study.
Topics: Acetates; Adult; Area Under Curve; Cohort Studies; Diabetes Mellitus, Type 2; Diacylglycerol O-Acyltransferase; Diglycerides; Dose-Response Relationship, Drug; Humans; Insulin Resistance; Intestinal Absorption; Male; Mass Spectrometry; Postprandial Period; Pyrazines; Treatment Outcome; Triglycerides | 2013 |
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Topics: Acetates; Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Diacylglycerol O-Acyltransferase; Diarrhea; Dose-Response Relationship, Drug; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Intestinal Absorption; Male; Middle Aged; Obesity; Peptide YY; Pyrazines; Treatment Outcome; Weight Loss | 2014 |
4 other study(ies) available for pyrazines and azd7687
| Article | Year |
|---|---|
Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).
Topics: Acetates; Animals; Diacylglycerol O-Acyltransferase; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Pyrazines; Rats; Solubility | 2012 |
Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse.
Topics: Acetates; Alopecia; Animals; Diacylglycerol O-Acyltransferase; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Insulin Resistance; Male; Mice; Mice, Inbred ICR; Mice, Knockout; Pyrazines; Sebaceous Glands; Skin | 2015 |
COPD biomarkers as tools for decision making in early clinical drug development.
Topics: Acetates; Biomarkers; Clinical Trials as Topic; Cluster Analysis; Endpoint Determination; Humans; Interleukin-6; Lung; Prognosis; Pulmonary Disease, Chronic Obstructive; Pyrazines | 2016 |
Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol.
Topics: Acetates; Animals; Biomarkers; Body Mass Index; Cohort Studies; Data Analysis; Diacylglycerol O-Acyltransferase; Dietary Fats; Glucose Tolerance Test; Healthy Volunteers; Humans; Lipid Metabolism; Male; Meals; Mice; Mice, Inbred ICR; Models, Biological; Pyrazines; Rats; Rats, Wistar; Species Specificity; Time Factors; Triglycerides | 2019 |